EraCal Therapeutics Ltd. develops a oral-active anti-obesity drug, a first-in-class appetite suppressor. This new chemical entity emerged from EraCal’s drug discovery platform, which also forms the basis of a research collaboration with Novo Nordisk.
Cooperation possibilities
In vivo drug discovery and/or validation, CNS active compounds, small molecule chemistry.
